Cipla is a large-cap pharmaceutical company belonging to Nifty 50 group of companies. Cipla Share Price reflects the current financial status of the company.
Cipla Share Price Graph
Cipla was incorporated in 1935 in the name of Chemical, Industrial & Pharmaceutical Laboratories by Khwaja Abdul Hamied. He had some proprietary formula for some drugs and medicines which he donated to the company without charging any royalty. Later, in the same year, the company was named Cipla and was registered as a limited company with a paid up capital of 6 lakhs rupees.
Currently, Cipla is a major name in the Indian drug market. It is a large-cap company belonging to the Nifty 50 group. The company has a strong global presence. 55% of its revenue comes from its business abroad. The company manufactures drugs for human and veterinary uses. It focuses on new formulations as well. Besides drugs, it has also forayed into the manufacture of bulk drug and pesticides. In addition, it earns its revenue from the business of food and beverages, oral hygiene products, personal care products, room fresheners and detergents.
Currently, Cipla has a presence in the drug market of 170 countries. Its manufacturing units are approved by world regulatory bodies like USFDA, WHO – Canada, UK – MHRA.
Cipla runs two institutes in the name of Cipla Cancer Palliative Care u0026amp; Training Centre and Dr K. A Hamied Institute.
Cipla has manufactured many pioneering drugs in India and abroad. Some of them are oral contraceptive pills in the name of i-Pill, CFC-free inhalers in US and Europe, generic version of drugs to treat H1N1 influenza for the local market, Touch Breast Scan (TBS) for non-evasive early stage breast cancer detection – among many others. Through a recent deal of Rs 95 crores, Piramal Healthcare has bought the intellectual property right of the drug i-Pill.
The company has received many awards for excellence in drug manufacturing field.
Cipla Share Price is Rs 534.75 (as on 19.06.17, 09.20 hrs.) in BSE. As per the latest data, the standalone basis P/E is 44.32 versus average industry PE of 28.41, EPS is Rs 12.12. Market cap is Rs 43,209 crores. The face value of a share is Rs 2.
Cipla share price was Rs 622.35 at the end of 23 October 2018 in the National Stock Exchange. The present market cap is Rs 50161.67 crores. The earning per share or EPS is Rs 19.87 as per the average share price of the trailing 12 months data. The price over earning ratio or P/E stands at 31.53. The Book Value per share is Rs 181.11. The price over book value ratio or P/BV 3.46. The Dividend yield is 0.48%. The 52 weeks high price is Rs 678.45 and 52 weeks low is Rs 507.20.
The quarter ending June 2018 reported a sales figure of Rs 3845.84 crores. Other operating income stands at Rs 93.15 crores. The operating profit stands at Rs 726.37 crores. Other income stands at Rs 170.11 crores. The EBITDA is Rs 896.48 crores. The net profit stands at Rs 451.25 crores. The earning per share or EPS of this quarter stands at Rs 5.59.
Cipla Ltd. is a Large Cap company operating in the Indian pharmaceuticals and healthcare sector.
Cipla earns its lions share of revenue from manufacture and sales of medicines in the form of tablets, capsules, injection ampules etc. The annual audited report ending at 31 March 2018 reported that Cipla Ltd. earning from sales of medicines in the form of tablets and capsules was Rs 6163.98 crores which amounted to 56.16% of total sales value. Sales of injections and sterile solutions contributed Rs 1506.33 crores amounting 13.72% of total sales, sales of Aerosols contributed Rs 1276.00 crores which is equivalent to 11.62% of total sales, Rs 862.17 crores were earned from sales of bulk drugs (7.85% of total sales value), sales of liquids contributed Rs Rs 466.89 crores and sales of Creams contributed Rs 307.84 crores amounting to 2.80% of the total sales value. Besides the above-mentioned sales figure, financial stats of the previous fiscal show that revenue earned from export incentives was Rs 162.31 crores (1.47% of total sales), revenue earned from operating income stood at Rs 112.22 crores (1.02% of total sales), earnings from other services were Rs 36.44 crores (0.33% of total sales value), earnings from other sources were Rs 53.87 crores and sales of scraps contributed a total of Rs 26.53 crores amounting to 0.24% of total sales.
The audited report ending on 30 June 2018 reported a consolidated sales of Rs 3845.84 crores which is up by 10.01% from the sales of last quarter ending on 31 March 2018 which was Rs 3495.81 crores and the total sales in this quarter has increased by 12.05% from the sales same quarter of the previous year which was Rs 3432.32 crores.
The top management of Cipla Ltd. includes Dr Y K Hamied, Dr Peter Mugyenyi, Mr Adil Zainulbhai, Mr Ashok Sinha, Mr M K Hamied, Mr S Radhakrishnan, Mr Peter Lankau, Mr Umang Vohra, Ms Naina Lal Kidwai, Ms Punita Lal, Ms Ireena Vittal and Ms Samina Vaziralli.
Cipla Ltd. has appointed M/S Walker Chandiok u0026amp; Company LLP as its auditor.
As on 30 September 2018, the company has a total number of 805,227,852 shares outstanding.
The shareholding pattern of the company currently has different shareholders in the manner as mentioned below.
- The promoters and promoter group of the company hold 117,803,409 nos of shares which is equivalent to 14.63% of total shares.
- The foreign institutions or FIIs hold 206,082,337 nos of shares amounting to 25.59% of total shares.
- The foreign promoters hold 177,682,187 nos of shares or 22.07% of shares.
- Others hold 61,453,997 nos or shares or 7.63% of total shares.
- The nationalised banks and mutual funds together hold 88,369,547 nos of shares or 10.97% of total shares.
- Other financial institutions hold 22,816,615 nos of shares amounting to 2.83% of total shares.
- General public holds 130,088,285 nos of shares which is equivalent to 16.16% of total shares.
- In addition, a total number of 921,485 nos shares which are equivalent to 0.11% of total shares are subscribed to GDR.
For more information on other companies, kindly visit the stock technicals page.